Transcriptomics

Dataset Information

0

Quisinostat is a brain-penetrant radiosensitizer in glioblastoma


ABSTRACT: In recent years, histone deacetylase inhibitors (HDACi) have garnered considerable interest for the treatment of adult and pediatric malignant brain tumors. However, owing to their broad-spectrum nature and inability to effectively penetrate the blood-brain barrier, HDACi have failed to provide significant clinical benefit to glioblastoma (GBM) patients to date. Moreover, global inhibition of HDACs results in widespread toxicity, highlighting the need for selective isoform targeting. While no isoform-specific HDACi are currently available, the second-generation hydroxamic acid-based HDACi quisinostat possesses sub-nanomolar specificity for class I HDAC isoforms, particularly HDAC1 and 2. Recently, we demonstrated that HDAC1 is the essential HDAC in GBM. Here, we panalyzed the neuro-pharmacokinetic, pharmacodynamic and radiation-sensitizing properties of quisinostat in preclinical models of GBM. We found that quisinostat is a well-tolerated and brain-penetrant molecule that significantly extended survival when administered in combination with radiation in vivo. The pharmacokinetic-pharmacodynamic-efficacy relationship was established by correlating free drug concentrations and evidence of target modulation in the brain with survival benefit. Together, these data provide a strong rationale for clinical development of quisinostat as a radiosensitizer for the treatment of GBM.

ORGANISM(S): Homo sapiens

PROVIDER: GSE241227 | GEO | 2023/11/23

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2013-01-11 | E-GEOD-43407 | biostudies-arrayexpress
2013-01-11 | GSE43407 | GEO
2010-12-27 | E-GEOD-26317 | biostudies-arrayexpress
2010-12-27 | GSE26317 | GEO
2013-06-08 | E-GEOD-47745 | biostudies-arrayexpress
2021-10-20 | GSE162788 | GEO
2021-10-20 | GSE162786 | GEO
2021-10-20 | GSE162785 | GEO
2019-04-10 | GSE129512 | GEO
| EGAD00001003810 | EGA